TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06667908: A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 130 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06667908 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06667908 Rescue Dossier →